Research graph
References from First-line durvalumab and tremelimumab in poor-prognosis unresectable hepatocellular carcinoma: Phase IIIb single-arm SIERRA study. Local targets link to admitted publications; unresolved targets remain external evidence.
Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
10.1016/j.annonc.2025.02.006 · 2025 · External reference
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
10.1016/j.jhep.2024.08.028 · 2025 · External reference
AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
10.1097/hep.0000000000000466 · 2023 · External reference
Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
10.1056/evidoa2100070 · 2022 · External reference
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
10.1056/nejmoa1915745 · 2020 · External reference
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial
10.1016/s0140-6736(25)00403-9 · 2025 · External reference
Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab
10.1002/cam4.3116 · 2020 · External reference
Treatment and the prognosis of hepatocellular carcinoma in Asia
10.1111/liv.15130 · 2022 · External reference
Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC
10.1016/j.jhep.2025.03.033 · 2025 · External reference
Real-world experiences using atezolizumab + bevacizumab for the treatment of unresectable hepatocellular carcinoma: a multicenter study
10.3390/cancers17111814 · 2025 · External reference
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study
10.1002/hep.32468 · 2022 · External reference
Effectiveness and safety of nivolumab in Child–Pugh B patients with hepatocellular carcinoma: a real-world cohort study
10.3390/cancers12071968 · 2020 · External reference
Characterization of the real-world first line (1L) use of single dose tremelimumab regular interval durvalumab (STRIDE), for treatment of unresectable hepatocellular carcinoma (uHCC), using two electronic medical record (EMR) databases
2025 · External reference
Efficacy and safety of atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma with main trunk and/or contralateral portal vein invasion in IMbrave150
2024 · External reference
CheckMate 040 cohort 5: a phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis
10.1016/j.jhep.2021.04.047 · 2021 · External reference
A multicenter, phase 2 study of atezolizumab plus bevacizumab (atezo+bev) combination therapy in patients with unresectable hepatocellular carcinoma (HCC) and Child–Pugh class B cirrhosis: CHALLENGE trial final results
10.1200/jco.2025.43.4_suppl.587 · 2025 · External reference
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
10.1016/j.annonc.2024.02.005 · 2024 · External reference
Pooled efficacy and safety outcomes with tremelimumab plus durvalumab in participants with unresectable hepatocellular carcinoma from the combined China extension and global cohorts in the Phase 3 HIMALAYA study
10.1016/j.annonc.2025.08.2124 · 2025 · External reference
Systemic treatment of HCC in special populations
10.1016/j.jhep.2020.11.026 · 2021 · External reference
Early safety results from the phase 3b SIERRA study of durvalumab and tremelimumab as first-line treatment for participants with unresectable hepatocellular carcinoma and a poor prognosis
10.1159/000549955 · 2025 · External reference
Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
10.1016/j.jhep.2021.11.030 · 2022 · External reference
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
10.1016/s0140-6736(23)00961-3 · 2023 · External reference
Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable HCC: HIMALAYA phase III randomized clinical trial
10.1097/hep.0000000000001385 · 2026 · External reference
Immunotherapy vs best supportive care for patients with hepatocellular cancer with Child-Pugh B dysfunction
10.1001/jamaoncol.2024.2166 · 2024 · External reference
Atezolizumab plus bevacizumab in patients with child–Pugh B advanced hepatocellular carcinoma
10.1177/17588359221148541 · 2023 · External reference
Real-world outcomes of combination immunotherapy in patients with Child–Pugh class B hepatocellular carcinoma
2026 · External reference
Portal vein tumor thrombosis in hepatocellular carcinoma patients: Is it the end?
10.1016/j.livres.2024.09.002 · 2024 · External reference
